Ritonavir News and Research

RSS

Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.

Should siRNA-based antivirals be added to the COVID toolbox?

A recent study reviewed the existing treatment modalities, including vaccines and antivirals, for SARS-CoV-2 infection.

19 Jul 2022

Paxlovid resistance associated with SARS-CoV-2 3CLpro mutations

In a recent study published in the bioRxiv* preprint server, researchers at the Medical University of Innsbruck assessed the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CLpro mutations responsible for Paxlovid resistance. The 3-chymotrypsin-like protease (3CLPro), or main protease (Mpro), is the main protease found in coronaviruses.

6 Jul 2022

SARS-CoV-2 can evade Paxlovid by multiple mechanisms

In a recent article posted to the bioRxiv* preprint server, researchers at Rutgers, the State University of New Jersey, the University of South Florida, and the Catholic University of America demonstrated that the natural severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) mutations result in nirmatrelvir resistance.

30 Jun 2022

SARS-CoV-2 3CLpro also susceptible to mutations

Researchers assess the activity of all potential mutations in the SARS-CoV-2 3CLpro.

29 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

Paxlovid is shown to be effective in treating COVID-19

In a recent Morbidity and Mortality Weekly Report (MMWR) published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers described cases of coronavirus disease 2019 (COVID-19)–related hospitalizations and emergency department (ED) visits in five to 15 days following Paxlovid (Nirmatrelvir/ritonavir ) treatment.

22 Jun 2022

Insufficient drug exposure most likely to cause COVID-19 rebound

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.

21 Jun 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Tracking the emergence of potential drug-resistant mutations in SARS-CoV-2 proteins

Researchers hypothesized that the emergence of resistant SARS-CoV-2 variants can be anticipated by identifying possible escape mutations already present in the existing SARS-CoV-2 populations.

1 Jun 2022

Prevalence of SARS-CoV-2 infection during Omicron BA.2/BA.2.12.1 surge in New York

Researchers surveyed a representative sample of the adult population of New York City, United States, to determine the prevalence of COVID-19.

30 May 2022

The effectiveness of molnupiravir and nirmatrelvir/ritonavir in reducing hospitalization and deaths in non-hospitalized COVID-19 patients

Researchers assessed the effectiveness of two orally administered antiviral medications, nirmatrelvir/ritonavir, and molnupiravir, in decreasing hospitalization and deaths among real-world non-hospitalized COVID-19 patients in Hong Kong.

25 May 2022

Insilico Medicine nominates novel preclinical candidate targeting 3CL protease for COVID-19 treatment

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19.

24 May 2022

Efficacy study of Paxlovid and Molnupiravir in real-world settings shows positive results

In a recent study posted to the medRxiv* pre-print server, researchers evaluated the effectiveness of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, molnupiravir (Lagevrio) or nirmatrelvir/ritonavir (Paxlovid) in a real-world setting.

24 May 2022

Evaluating efficacy of SARS-CoV-2 antivirals in a mouse model

In a recent study posted to the bioRxiv* pre-print server, researchers from Belgium evaluated the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drugs in a severe combined immunodeficient (SCID) mouse model.

18 May 2022

Researchers explore COVID-19 vaccination in immunocompromised individuals

A new study discusses the safety and efficacy of the COVID-19 vaccination and potential strategies to optimize protection in patients with impaired immunity.

17 May 2022

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

A new paper describes a new epidemiological model of SARS-CoV-2 transmission that includes the burden of COVID-19, vaccination coverage, available antiviral therapies, and non-pharmaceutical interventions.

12 May 2022

First oral antiviral approved for early treatment of COVID-19

The United States Food and Drug Administration granted an Emergency Use Authorization in December 2021 for the first oral antiviral, a pill containing two protease inhibitors – nirmatrelvir and ritonavir (Paxlovid, Pfizer) – for early treatment of COVID-19.

11 May 2022

Outcomes of COVID-19 treatment with Paxlovid

Researchers investigated the outcomes of COVID-19 treatment with paxlovid.

5 May 2022

Oral Nirmatrelvir's effects on long COVID symptoms

In a recent study posted to the Research Square* preprint server, researchers at the University of California, San Francisco, examined the cases of three individuals who received nirmatrelvir/ritonavir antiviral therapy at different stages following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

4 May 2022

SARS-CoV-2 Mpro inhibitors built on rattlesnake venom scaffold

A new study describes the development of new molecules with inhibitory activity against the SARS-CoV-2 viral main protease (Mpro) enzyme, based on rattlesnake venom.

29 Apr 2022